- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00290420
Prevention of P. Vivax Malaria During Pregnancy in Bolivia
May 21, 2013 updated by: Bernadette Murgue, Institut de Recherche pour le Developpement
Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine.
The purpose of this study is to determine which, between weekly prophylaxis or malaria attack treatment, both by chloroquine, is the most appropriate way to protect women and foetus from P. vivax malaria infection during pregnancy.
Study Overview
Detailed Description
It has been demonstrated that malaria is responsible for anaemia during pregnancy and reduces birth weight among newborns.
In Bolivia, malaria is mostly caused by P. vivax.
Maternal and foetal consequences of P. vivax infections have been poorly investigated until now, over all in South America.
In fact, recommendations for the protection of pregnant women from malaria in Bolivia have not been clearly established.
Prophylaxis by chloroquine is still recommended in other continents than Africa, mainly because chloroquine resistances are still uncommon in P. vivax species.
The alternative way to protect women during pregnancy is to treat malaria attacks during antenatal visits.
For this purpose, we will realize a study in order to assess the most appropriate way to protect women and foetus from malaria infection, i.e. weekly prophylaxis or mild malaria attack treatment, both by chloroquine.
By realizing a randomized and multicentric clinical trial on 800 women in each group, we will compare the impact on maternal malaria attack incidence rates, on proportions of mothers with anaemia, on low-birth weight and on positive parasitaemias during pregnancy and at delivery, of weekly prophylaxis and mild malaria attack diagnosis and treatment.
The study will be undertaken during 18 months in the region of Santa Cruz and will give important information to the Bolivian Ministry of Health for establishing national recommendations.
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Pregnancy between 4 to 36 weeks of gestation
- Intention to deliver at the maternity clinics
- Residence near the maternity clinics
- Written informed consent (parents or tutors if aged<18 years)
Exclusion Criteria:
- Pregnancy prior to 4 weeks or after 36 weeks of gestation
- Allergy to chloroquine
- Clinical signs of hepatic or renal alteration
- Inability to take drugs by oral route
- Presence of effective uterine contractions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Chloroquine profilaxis
Prevention: chloroquine profilaxis Prevention of malaria attacks with chloroquine profilaxis taken once a week |
Prevention: Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes
Other Names:
|
|
No Intervention: No prevention
Treatment of malaria attack with chloroquine when they occur
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of women presenting a malaria attack during pregnancy
Time Frame: two years
|
two years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportions of mothers with placental plasmodial infection
Time Frame: 2 years
|
2 years
|
|
proportions of mothers with moderate to severe anaemia (<8g/dl) at delivery
Time Frame: 2 years
|
2 years
|
|
maternal haemoglobin rate at delivery
Time Frame: 2 years
|
2 years
|
|
proportions of women with parasitaemia during pregnancy and at delivery
Time Frame: 2 years
|
2 years
|
|
mean parasites densities of women with parasitaemia during pregnancy and at delivery
Time Frame: 2 years
|
2 years
|
|
proportions of children with low birthweight (<2,500 grams)
Time Frame: 2 years
|
2 years
|
|
mean birthweight
Time Frame: 2 years
|
2 years
|
|
proportions of preterm deliveries
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Michel Cot, MD-PhD, Institut de Recherche pour le Developpement
- Study Director: Laurent Brutus, MD-MSc, Institut de Recherche pour le Développement, IRD, Bolivia
- Principal Investigator: Agnès Le Port, MSc, Institut de Recherche pour le Développement, IRD, Bolivia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Anticipated)
November 1, 2007
Study Completion (Anticipated)
November 1, 2007
Study Registration Dates
First Submitted
February 9, 2006
First Submitted That Met QC Criteria
February 9, 2006
First Posted (Estimate)
February 13, 2006
Study Record Updates
Last Update Posted (Estimate)
May 22, 2013
Last Update Submitted That Met QC Criteria
May 21, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRD/Prevmal/Bol/06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.